[Federal Register Volume 86, Number 179 (Monday, September 20, 2021)]
[Notices]
[Pages 52158-52160]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-20268]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Findings of research misconduct have been made against Ya 
Wang, M.D., Ph.D. (Respondent), retired Professor and Director, 
Division of Experimental Radiation Oncology, Department of Radiation 
Oncology, Winship Cancer Institute, Emory University (EU). Respondent 
engaged in research misconduct in research supported by U.S. Public 
Health Service (PHS) funds, specifically National Cancer Institute 
(NCI), National Institutes of Health (NIH), grants P30 CA138292 and R01 
CA186129 and National Institute of General Medical Sciences (NIGMS), 
NIH, grant R01 GM080771. The administrative actions, including 
debarment for a period of four (4) years, were implemented beginning on 
August 4, 2021, and are detailed below.

FOR FURTHER INFORMATION CONTACT:  Wanda K. Jones, Dr. P.H., Acting 
Director, Office of Research Integrity,

[[Page 52159]]

1101 Wootton Parkway, Suite 240, Rockville, MD 20852, (240) 453-8200.

SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of 
Research Integrity (ORI) has taken final action in the following case:
    Ya Wang, M.D., Ph.D., Emory University: Based on the report of an 
inquiry conducted by EU and analysis conducted by ORI in its oversight 
review, ORI found that Dr. Ya Wang, retired Professor and Director, 
Division of Experimental Radiation Oncology, Department of Radiation 
Oncology, Winship Cancer Institute, EU, engaged in research misconduct 
in research supported by PHS funds, specifically NCI, NIH, grants P30 
CA138292 and R01 CA186129 and NIGMS, NIH, grant R01 GM080771.
    Respondent neither admits nor denies ORI's findings of research 
misconduct. The settlement is not an admission of liability on the part 
of the Respondent. The parties entered into a Voluntary Exclusion 
Agreement to conclude this matter without further expenditure of time, 
finances, or other resources.
    ORI found that Respondent engaged in research misconduct by 
knowingly, intentionally, and/or recklessly falsifying data that were 
included in the following one (1) PHS grant application and six (6) 
published papers:
    <bullet> R21 HL154577-01, ``GPRC5A Inhibits Error-Prone Repair to 
Maintain Lung Genomic Integrity,'' submitted to the National Heart, 
Lung, and Blood Institute (NHLBI), NIH, on December 13, 2019.
    <bullet> miR-21-Mediated Radioresistance Occurs via Promoting 
Repair of DNA Double Strand Breaks. J Biol Chem. 2017 Feb 
24;292(8):3531-40; doi: 10.1074/jbc.M116.772392 (hereafter referred to 
as ``J Biol Chem. 2017''). Retraction in: J Biol Chem. 2020 May 
1;295(18):6250; doi: 10.1074/jbc.W120.013725.
    <bullet> Distinct Roles of Ape1 Protein, an Enzyme Involved in DNA 
Repair, in High or Low Linear Energy Transfer Ionizing Radiation-
Induced Cell Killing. J Biol Chem. 2014 Oct 31; 289(44):30635-44; doi: 
10.1074/jbc.M114.604959 (hereafter referred to as ``J Biol Chem. 
2014''). Retraction in: J Biol Chem. 2020 May 1;295(18):6249; doi: 
10.1074/jbc.W120.013724.
    <bullet> OCT4 as a Target of miR-34a Stimulates p63 but Inhibits 
p53 to Promote Human Cell Transformation. Cell Death Dis. 2014 Jan 
23;5(1):e1024; doi: 10.1038/cddis.2013.563 (hereafter referred to as 
``Cell Death Dis. 2014'').
    <bullet> MicroRNA-21 Modulates the Levels of Reactive Oxygen 
Species by Targeting SOD3 and TNF[alpha]. Cancer Res. 2012 Sep 
15;72(18):4707-13; doi: 10.1158/0008-5472.CAN-12-0639 (hereafter 
referred to as ``Cancer Res. 2012a'').
    <bullet> RNAi-Mediated Targeting of Noncoding and Coding Sequences 
in DNA Repair Gene Messages Efficiently Radiosensitizes Human Tumor 
Cells. Cancer Res. 2012 Mar 1; 72(5):1221-8; doi: 10.1158/0008-
5472.CAN-11-2785 (hereafter referred to as ``Cancer Res. 2012b'').
    <bullet> Over-Expression of miR-100 is Responsible for the Low-
Expression of ATM in the Human Glioma Cell Line: M059J. DNA Repair 
(Amst). 2010 Nov 10;9(11):1170-5; doi: 10.1016/j.dnarep.2010.08.007 
(hereafter referred to as ``DNA Repair 2010'').
    ORI found that respondent knowingly, intentionally, and/or 
recklessly falsified protein immunoblot data by reusing and relabeling 
the same images to represent different experimental conditions in 
mammalian tissue culture models of DNA damage and repair in eighteen 
(18) figure panels in eleven (11) figures in one (1) grant application 
and six (6) published papers.
    Specifically:
    <bullet> Western blot images for total protein expression in 
distinct transgenic mouse cell lines were falsified by reusing 
immunoblot bands and relabeling them to represent different experiments 
in eleven (11) figure panels in two (2) papers, including:

--Figure 3D in J Biol Chem. 2017, representing [beta]-actin expression 
(left side panel) in wildtype (WT), microRNA-21 (miR-21) knock-in, and 
miR-21<SUP>-/-</SUP> mouse embryonic fibroblast (MEF) cells exposed to 
irradiation
--Figure 4C in J Biol Chem. 2017, representing DNA-PKcs expression in 
miR-21 knock-in MEF cells exposed to irradiation
--Figure 5A in J Biol Chem. 2017, representing CDC25A and [beta]-actin 
expression in WT, GSK3B<SUP>-/-</SUP>, and Cyclin D1<SUP>-/-</SUP> MEF 
cells transfected with control or gene-specific silencing RNA (siRNA)
--Figure 1 in J Biol Chem. 2014, representing [beta]-actin expression 
in Ku80<SUP>-/-</SUP> (Figure 1A) and Ogg1<SUP>-/-</SUP> (Figure 1C) 
MEF cells transfected with expression or control vectors
--Figure 3 in J Biol Chem. 2014, representing H2A expression in WT MEF 
(Figure 3A), Ku80<SUP>-/-</SUP> MEF (Figure 3B), Ogg1<SUP>-/-</SUP> MEF 
(Figure 3C), and Ogg1\+\ (rescue) MEF (Figure 3D) cells transfected 
with expression or control vectors and in the absence or presence of 
radiation exposure
--Figure 3D in J Biol Chem. 2014, representing Mre11 (left panel) 
expression in Ogg1\+\ (rescue) MEF cells transfected with expression or 
control vectors in the absence or presence of radiation exposure
--Figure 4B in J Biol Chem. 2014, representing Mre11 expression in 
Ogg1<SUP>-/-</SUP> MEF cells with control or Ape1 expression vector in 
the presence of low or high linear energy transfer (LET) irradiation
--Figure 5C in J Biol Chem. 2014, representing Ape1 and [beta]-actin 
expression in WT MEF cells with or without gene depletion and 
transfected with control or various Ape1 expression vectors

    <bullet> western blot images for total protein expression in human 
cell lines subject to gene depletion and/or overexpression were 
falsified by reusing immunoblot bands and relabeling them to represent 
different experiments in seven (7) figure panels in five (5) papers and 
one (1) grant application, including:

--Figure 4A in NIH grant application R21 HL154577-01, representing 
GPRC5A levels in different patient-derived cell lines with gene 
suppression or depletion
--Figure 4D in J Biol Chem. 2017, representing total DNA-PKcs, 
phosphorylated DNA-PKcs, CDC25A, and GSK3B levels in human embryonic 
kidney cells transfected with controls or various expression vectors 
and/or miR-21 mimics
--Figure 5C in J Biol Chem. 2017, representing CDC25A, GSK3B, Cyclin 
D1, and [beta]-actin expression in human embryonic kidney cells with or 
without gene depletion and transfected with controls or miR-21 mimics
--Figure 5B in Cell Death Dis. 2014, representing p53 and p63 levels in 
human lung epithelial cells with or without gene depletion
--Figure 3A in Cancer Res. 2012a, representing TNF[alpha] levels in 
control and miR-21 overexpressing human lung epithelial cells at 
different time points following irradiation
--Figure 5A in Cancer Res. 2012b, representing XRCC4 levels in both 
human lung and brain epithelial cells with gene depletion at multiple 
time points and treated with or without an artificial microRNA
--Figure 3A in DNA Repair 2010, representing ATM and Ku70 levels in 
human glioblastoma-derived cells with or without gene depletion

    <bullet> western blot images for proteins from chromatin DNA 
complexes in mouse cell lines transfected with control or expression 
vectors and in the absence or presence of irradiation were falsified by 
reusing immunoblot bands

[[Page 52160]]

and relabeling them to represent different experiments in three (3) 
figure panels in one (1) paper, including:
--Figure 3 in J Biol Chem. 2014, representing chromatin-bound [gamma]-
H2AX levels in WT MEF (Figure 3A), Ogg1<SUP>-/-</SUP> MEF (Figure 3C), 
and Ogg1\+\ (rescue) MEF (Figure 3D) cells transfected with a control 
or expression vector and in the absence or presence of irradiation

    Dr. Wang entered into a Voluntary Exclusion Agreement (Agreement) 
and voluntarily agreed to the following:
    (1) Respondent agreed to exclude herself voluntarily for a period 
of four (4) years beginning on August 4, 2021, from any contracting or 
subcontracting with any agency of the United States Government and from 
eligibility for or involvement in nonprocurement programs of the United 
States Government referred to as ``covered transactions'' pursuant to 
HHS' Implementation (2 CFR part 376) of OMB Guidelines to Agencies on 
Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively 
the ``Debarment Regulations'').
    (2) Respondent agreed to exclude herself voluntarily from serving 
in any advisory capacity to PHS including, but not limited to, service 
on any PHS advisory committee, board, and/or peer review committee, or 
as a consultant for a period of four (4) years, beginning on August 4, 
2021.
    (3) As a condition of the Agreement, Respondent will request that 
the following papers be corrected or retracted in accordance with 42 
CFR 93.407(a)(1) and Sec.  93.411(b):

<bullet> Cell Death Dis. 2014 Jan;5(1):e1024
<bullet> Cancer Res. 2012 Sep 15;72(18):4707-13
<bullet> Cancer Res. 2012 Mar 1;72(5):1221-8
<bullet> DNA Repair (Amst). 2010 Nov 10;9(11):1170-5

    Respondent will copy ORI and the Research Integrity Officer at EU 
on the correspondence.

    Dated: September 15, 2021.
Wanda K. Jones,
Acting Director, Office of Research Integrity, Office of the Assistant 
Secretary for Health.
[FR Doc. 2021-20268 Filed 9-17-21; 8:45 am]
BILLING CODE 4150-31-P